MDMA: Studies point to the substance's efficacy in treating PTSD

The use of MDMA (3,4-methylenedioxymethamphetamine) in combating Post-Traumatic Stress Disorder (PTSD) still generates debates, but its clinical efficacy is gaining recognition. According to Dr. Lucas Cury, postgraduate in Neurology from PUC-Rio, this data signals a paradigm shift.

Contrary to medications focused solely on symptom suppression, MDMA offers a new perspective on pain. Cury explains that the substance acts as a kind of "neural network recycling".

This process helps break repetitive patterns of behavior and perception that keep the patient trapped in suffering. The specialist emphasizes, however, that MDMA is not a "magic pill".

The substance is a tool that, combined with psychotherapy, has the potential for healing where there was previously only containment. “The recommended use should follow a strict protocol, under the control of duly qualified professionals and only in a clinical setting,” he points out.

Cury highlights that this rigor is essential for the durability of the benefits. The goal is for the positive effects not to be restricted only to the session.

What is MDMA and its action in the brain

Synthesized in 1912, MDMA remained decades without clinical use, but today its biological action is better understood. Dr. Lucas defines the effect as a "serotonin storm", an intense release of serotonin that generates well-being.

The process occurs alongside the release of oxytocin, a hormone linked to emotional bonds and empathy. The major differential for trauma treatment is that MDMA reduces the hyperconnectivity of the amygdala, a brain region associated with fear.

“This allows the patient to observe traumatic experiences with more sobriety and lucidity,” says Cury. Clinically, there is an attenuation of social phobia and a greater capacity for interpersonal connection.

Different from classic psychedelics that alter visual perception, MDMA is classified as an empathogen. Its main function is to promote an emotional state favorable to communication.

This is essential for the patient to be able to verbalize painful events without the brain going into defense mode. “MDMA is not an isolated treatment, but a piece of a broader therapeutic project,” emphasizes the doctor.

Safety and risks of MDMA treatment

The specialist issues an important warning about the confusion between therapeutic and recreational use. Illegally sold drugs often do not contain the correct active ingredient or have dangerous adulterations.

Therefore, Cury argues that the safety of MDMA treatment is based on three pillars: standardized substance, controlled environment, and continuous monitoring. In the medical protocol, administration is oral and constantly monitored.

Patients with chronic PTSD or a history of severe traumas are the main candidates for benefit. The doctor also points out the potential to treat deep emotional blockages and social phobia.

Regulatory scenario and the future of MDMA

Research has advanced significantly through the Multidisciplinary Association for Psychedelic Studies (MAPS). The organization funded crucial clinical trials to prove the safety of MDMA.

Currently, the substance is in the final stages of review by the FDA in the United States. In 2023, Australia became a pioneer in legally approving psychedelic-assisted therapy.

In Brazil, importation is only allowed via Anvisa for individual cases. Dr. Lucas Cury expects that international advancements will drive national regulation.

The doctor believes that incorporating this treatment will be a vital step for mental health in the country. Thousands of Brazilians await more effective alternatives to deal with their traumas.